| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = $489,977 ) |
| | 2026 | 2026 | THE GENEVA FOUNDATION | 950 BROADWAY STE 307 | TACOMA | WA | 98402-4454 | PIERCE | USA | U3REP260786 | Trauma Care Readiness and Coordination Cooperative Agreement | 00 | 1 | ASPR | 9/28/2026 | $500,000 |
| | 2026 | 2023 | THE GENEVA FOUNDATION | 950 BROADWAY STE 307 | TACOMA | WA | 98402-4454 | PIERCE | USA | R21AI171817 | Identification of Genetic Markers of Susceptibility to Intracellular Bacterial Infection Using the Collaborative Cross Mouse Model | 000 | 2 | NIH | 2/12/2026 | -$10,023 |
|
 | Issue Date FY: 2025 ( Subtotal = -$89,722 ) |
| | 2025 | 2022 | THE GENEVA FOUNDATION | 950 BROADWAY STE 307 | TACOMA | WA | 98402-4454 | PIERCE | USA | R21AI156850 | A platform for genome mining of multidrug-resistant pathogens to develop therapeutic phages using synthetic biology | 000 | 2 | NIH | 6/9/2025 | -$1,816 |
| | 2025 | 2021 | THE GENEVA FOUNDATION | 950 BROADWAY STE 307 | TACOMA | WA | 98402-4454 | PIERCE | USA | R01AI132313 | Advancing a Candidate Polyclonal Antibody Therapy for Hantavirus Disease | 000 | 5 | NIH | 3/11/2025 | -$87,906 |
|
 | Issue Date FY: 2024 ( Subtotal = $0 ) |
| | 2024 | 2022 | THE GENEVA FOUNDATION | 950 BROADWAY STE 307 | TACOMA | WA | 98402-4454 | PIERCE | USA | R21AI156850 | A platform for genome mining of multidrug-resistant pathogens to develop therapeutic phages using synthetic biology | 000 | 2 | NIH | 1/24/2024 | $0 |
| | 2024 | 2020 | THE GENEVA FOUNDATION | 950 BROADWAY STE 307 | TACOMA | WA | 98402-4454 | PIERCE | USA | R21NS110556 | Soman-induced neuropathology in Gottingen minipig: large animal model assessment for MCM | 000 | 2 | NIH | 2/8/2024 | $0 |
|
 | Issue Date FY: 2023 ( Subtotal = $194,919 ) |
| | 2023 | 2023 | THE GENEVA FOUNDATION | 917 PACIFIC AVE | TACOMA | WA | 98402-4437 | PIERCE | USA | R21AI171817 | Identification of Genetic Markers of Susceptibility to Intracellular Bacterial Infection Using the Collaborative Cross Mouse Model | 000 | 2 | NIH | 7/18/2023 | $171,704 |
| | 2023 | 2021 | THE GENEVA FOUNDATION | 917 PACIFIC AVE | TACOMA | WA | 98402-4437 | PIERCE | USA | R01AI132313 | Advancing a Candidate Polyclonal Antibody Therapy for Hantavirus Disease | 000 | 5 | NIH | 7/4/2023 | $0 |
| | 2023 | 2018 | THE GENEVA FOUNDATION | 950 BROADWAY STE 307 | TACOMA | WA | 98402-4454 | PIERCE | USA | R01AI111516 | Mammalian and Plant-derived Antibody-based Therapies against Sudan Ebolavirus | 000 | 5 | NIH | 4/14/2023 | $23,215 |
|
 | Issue Date FY: 2022 ( Subtotal = -$153,196 ) |
| | 2022 | 2022 | GENEVA FOUNDATION, THE | 917 PACIFIC AVE STE 600 | TACOMA | WA | 98402-4437 | PIERCE | USA | R21AI156850 | A platform for genome mining of multidrug-resistant pathogens to develop therapeutic phages using synthetic biology | 000 | 2 | NIH | 1/12/2022 | $169,109 |
| | 2022 | 2022 | GENEVA FOUNDATION, THE | 917 PACIFIC AVE STE 600 | TACOMA | WA | 98402-4437 | PIERCE | USA | R21AI171817 | Identification of Genetic Markers of Susceptibility to Intracellular Bacterial Infection Using the Collaborative Cross Mouse Model | 000 | 1 | NIH | 7/27/2022 | $215,433 |
| | 2022 | 2020 | GENEVA FOUNDATION, THE | 917 PACIFIC AVE STE 600 | TACOMA | WA | 98402-4437 | PIERCE | USA | R21NS110556 | Soman-induced neuropathology in Gottingen minipig: large animal model assessment for MCM | 000 | 2 | NIH | 5/24/2022 | $0 |
| | 2022 | 2018 | GENEVA FOUNDATION, THE | 917 PACIFIC AVE STE 600 | TACOMA | WA | 98402-4437 | PIERCE | USA | R01AI111516 | Mammalian and Plant-derived Antibody-based Therapies against Sudan Ebolavirus | 000 | 5 | NIH | 12/6/2021 | -$263,493 |
| | 2022 | 2017 | GENEVA FOUNDATION, THE | 917 PACIFIC AVE STE 600 | TACOMA | WA | 98402-4437 | PIERCE | USA | R01AI105383 | Preclinical Assessment of a Multi-Head Electroporation Device for Delivery of Bio | 000 | 5 | NIH | 9/2/2022 | -$274,244 |
|
 | Issue Date FY: 2021 ( Subtotal = $483,673 ) |
| | 2021 | 2021 | GENEVA FOUNDATION, THE | 917 PACIFIC AVE STE 600 | TACOMA | WA | 98402-4437 | PIERCE | USA | R01AI132313 | Advancing a Candidate Polyclonal Antibody Therapy for Hantavirus Disease | 000 | 5 | NIH | 7/14/2021 | $379,859 |
| | 2021 | 2021 | GENEVA FOUNDATION, THE | 917 PACIFIC AVE STE 600 | TACOMA | WA | 98402-4437 | PIERCE | USA | R21AI156850 | A platform for genome mining of multidrug-resistant pathogens to develop therapeutic phages using synthetic biology | 000 | 1 | NIH | 2/18/2021 | $103,947 |
| | 2021 | 2018 | GENEVA FOUNDATION, THE | 917 PACIFIC AVE STE 600 | TACOMA | WA | 98402-4437 | PIERCE | USA | R21NS103820 | The carboxylesterase knockout mouse as a model to evaluate the efficacy of delayed medical countermeasures against soman exposure | 001 | 2 | NIH | 5/18/2021 | -$133 |
| | 2021 | 2018 | GENEVA FOUNDATION, THE | 917 PACIFIC AVE STE 600 | TACOMA | WA | 98402-4437 | PIERCE | USA | R21NS103820 | The carboxylesterase knockout mouse as a model to evaluate the efficacy of delayed medical countermeasures against soman exposure | 000 | 2 | NIH | 11/23/2020 | $0 |
|
 | Issue Date FY: 2020 ( Subtotal = $1,203,758 ) |
| | 2020 | 2020 | GENEVA FOUNDATION, THE | 917 PACIFIC AVE STE 600 | TACOMA | WA | 98402-4437 | PIERCE | USA | R01AI132313 | Advancing a Candidate Polyclonal Antibody Therapy for Hantavirus Disease | 000 | 4 | NIH | 7/6/2020 | $1,049,794 |
| | 2020 | 2020 | GENEVA FOUNDATION, THE | 917 PACIFIC AVE STE 600 | TACOMA | WA | 98402-4437 | PIERCE | USA | R21NS110556 | Soman-induced neuropathology in Gottingen minipig: large animal model assessment for MCM | 000 | 2 | NIH | 5/4/2020 | $153,964 |
| | 2020 | 2018 | GENEVA FOUNDATION, THE | 917 PACIFIC AVE STE 600 | TACOMA | WA | 98402-4437 | PIERCE | USA | R01AI111516 | Mammalian and Plant-derived Antibody-based Therapies against Sudan Ebolavirus | 000 | 5 | NIH | 6/25/2020 | $0 |
| | 2020 | 2017 | GENEVA FOUNDATION, THE | 917 PACIFIC AVE STE 600 | TACOMA | WA | 98402-4437 | PIERCE | USA | R01AI105383 | Preclinical Assessment of a Multi-Head Electroporation Device for Delivery of Bio | 000 | 5 | NIH | 8/5/2020 | $0 |
|
 | Issue Date FY: 2019 ( Subtotal = $1,265,113 ) |
| | 2019 | 2019 | GENEVA FOUNDATION, THE | 917 PACIFIC AVE STE 600 | TACOMA | WA | 98402-4437 | PIERCE | USA | R21NS110556 | Soman-induced neuropathology in Gottingen minipig: large animal model assessment for MCM | 000 | 1 | NIH | 4/25/2019 | $185,898 |
| | 2019 | 2019 | GENEVA FOUNDATION, THE | 917 PACIFIC AVE STE 600 | TACOMA | WA | 98402-4437 | PIERCE | USA | R01AI132313 | Advancing a Candidate Polyclonal Antibody Therapy for Hantavirus Disease | 000 | 3 | NIH | 7/11/2019 | $1,079,215 |
| | 2019 | 2017 | GENEVA FOUNDATION, THE | 917 PACIFIC AVE STE 600 | TACOMA | WA | 98402-4437 | PIERCE | USA | R01AI105383 | Preclinical Assessment of a Multi-Head Electroporation Device for Delivery of Bio | 000 | 5 | NIH | 3/27/2019 | $0 |
| | 2019 | 2016 | GENEVA FOUNDATION, THE | 917 PACIFIC AVE STE 600 | TACOMA | WA | 98402-4437 | PIERCE | USA | R01AI098933 | Advancing a Lead Candidate Hantavirus Pulmonary Syndrome DNA Vaccine | 000 | 5 | NIH | 1/7/2019 | $0 |
| | 2019 | 2016 | GENEVA FOUNDATION, THE | 917 PACIFIC AVE STE 600 | TACOMA | WA | 98402-4437 | PIERCE | USA | R01AI105383 | Preclinical Assessment of a Multi-Head Electroporation Device for Delivery of Bio | 002 | 4 | NIH | 9/5/2019 | $295,498 |
| | 2019 | 2015 | GENEVA FOUNDATION, THE | 917 PACIFIC AVE STE 600 | TACOMA | WA | 98402-4437 | PIERCE | USA | R01AI105383 | Preclinical Assessment of a Multi-Head Electroporation Device for Delivery of Bio | 001 | 3 | NIH | 9/5/2019 | -$295,498 |
|
 | Issue Date FY: 2018 ( Subtotal = $1,975,698 ) |
| | 2018 | 2018 | GENEVA FOUNDATION, THE | 917 PACIFIC AVE STE 600 | TACOMA | WA | 98402-4437 | PIERCE | USA | R01AI111516 | Mammalian and Plant-derived Antibody-based Therapies against Sudan Ebolavirus | 000 | 5 | NIH | 6/15/2018 | $786,345 |
| | 2018 | 2018 | GENEVA FOUNDATION, THE | 917 PACIFIC AVE STE 600 | TACOMA | WA | 98402-4437 | PIERCE | USA | R21NS103820 | The carboxylesterase knockout mouse as a model to evaluate the efficacy of delayed medical countermeasures against soman exposure | 000 | 2 | NIH | 8/22/2018 | $149,750 |
| | 2018 | 2018 | GENEVA FOUNDATION, THE | 917 PACIFIC AVE STE 600 | TACOMA | WA | 98402-4437 | PIERCE | USA | R01AI132313 | Advancing a Candidate Polyclonal Antibody Therapy for Hantavirus Disease | 000 | 2 | NIH | 7/20/2018 | $1,055,169 |
| | 2018 | 2016 | GENEVA FOUNDATION, THE | 917 PACIFIC AVE STE 600 | TACOMA | WA | 98402-4437 | PIERCE | USA | R33AI101387 | Targeting Cellular Processes to Counter the Effects of BoNT Intoxication | 001 | 5 | NIH | 6/4/2018 | -$12,470 |
| | 2018 | 2015 | GENEVA FOUNDATION, THE | 917 PACIFIC AVE STE 600 | TACOMA | WA | 98402-4437 | PIERCE | USA | R01AI096215 | Integrated polymer microfluidic device for multiplex diagnosis of viral infection | 000 | 5 | NIH | 2/1/2018 | -$15,566 |
| | 2018 | 2014 | GENEVA FOUNDATION, THE | 917 PACIFIC AVE STE 600 | TACOMA | WA | 98402-4437 | PIERCE | USA | R33AI101387 | Targeting Cellular Processes to Counter the Effects of BoNT Intoxication | 000 | 3 | NIH | 4/9/2018 | $12,470 |
|
 | Issue Date FY: 2017 ( Subtotal = $2,919,338 ) |
| | 2017 | 2017 | GENEVA FOUNDATION, THE | 917 PACIFIC AVE STE 600 | TACOMA | WA | 98402-4437 | PIERCE | USA | R01AI132313 | Advancing a Candidate Polyclonal Antibody Therapy for Hantavirus Disease | 000 | 1 | NIH | 8/18/2017 | $1,037,264 |
| | 2017 | 2017 | GENEVA FOUNDATION, THE | 917 PACIFIC AVE STE 600 | TACOMA | WA | 98402-4437 | PIERCE | USA | R01AI105383 | Preclinical Assessment of a Multi-Head Electroporation Device for Delivery of Bio | 000 | 5 | NIH | 3/14/2017 | $785,031 |
| | 2017 | 2017 | GENEVA FOUNDATION, THE | 917 PACIFIC AVE STE 600 | TACOMA | WA | 98402-4437 | PIERCE | USA | R01AI111516 | Mammalian and Plant-derived Antibody-based Therapies against Sudan Ebolavirus | 000 | 4 | NIH | 5/16/2017 | $917,343 |
| | 2017 | 2017 | GENEVA FOUNDATION, THE | 917 PACIFIC AVE STE 600 | TACOMA | WA | 98402-4437 | PIERCE | USA | R21NS103820 | The carboxylesterase knockout mouse as a model to evaluate the efficacy of delayed medical countermeasures against soman exposure | 000 | 1 | NIH | 9/22/2017 | $179,700 |
|
 | Issue Date FY: 2016 ( Subtotal = $2,256,352 ) (Continued on the next page) |
| | 2016 | 2016 | THE GENEVA FOUNDATION | POST OFFICE BOX 98687 | LAKEWOOD | WA | 98498 | PIERCE | USA | R01AI111516 | Mammalian and Plant-derived Antibody-based Therapies against Sudan Ebolavirus | 001 | 3 | NIH | 5/26/2016 | -$766,924 |
|